To Evaluate Safety, Tolerability and Pharmacological Effects of PU AD in Subjects With Mild AD Dementia

Condition:   Alzheimer Disease Interventions:   Radiation: Tau Positron emission tomography (PET);   Radiation: Fluorodeoxyglucose (FDG) Positron emission tomography (PET);   Diagnostic Test: Cerebrospinal fluid (CSF) Biomarkers;   Diagnostic Test: Blood Biomarkers;   Behavioral: Rating Scales;   Drug: PU-AD;   Drug: Placebo Sponsor:   Samus Therapeutics, Inc. Not yet recruiting

Source: ClinicalTrials.gov - March 17, 2020 Category: Research Source Type: clinical trials